PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12646262-8	2003	The addition of butyrolactone I, which is an inhibitor of CDK1 and CDK2, to the p53-negative cells reduced the floating round cell population and induced the disappearance of cyclin B1.	4-Butyrolactone	16-29	cyclin dependent kinase 2	Homo sapiens	67-71	
11329882-4	2000	We also found that butyrolactone I inhibits the CDK2 activity and enhances cell survival after an X-ray irradiation or doxorubicin treatment in both DLD1 (p21-/-) and DLD1 (p21+/+) cells.	4-Butyrolactone	19-32	cyclin dependent kinase 2	Homo sapiens	48-52	
10226033-7	1999	Remarkably, inhibition of the Cdk2 activity in HU-treated cells with butyrolactone I or roscovitine [6], or by expression of the Cdk inhibitor p21(Waf1/Cip1), blocked the continued centrosome duplication.	4-Butyrolactone	69-82	cyclin dependent kinase 2	Homo sapiens	30-34	
10373534-6	1999	This cellular kinase activity is sensitive to transfection of a dominant negative form of CDK2 as well as the application of the CDK inhibitors p21 and butyrolactone I but not p16.	4-Butyrolactone	152-165	cyclin dependent kinase 2	Homo sapiens	90-94	
9891485-0	1998	Suppression of albumin and alpha-fetoprotein gene expression by butyrolactone I, a selective inhibitor of the cdk family, in HuH-7 human hepatoma cells.	4-Butyrolactone	64-77	cyclin dependent kinase 2	Homo sapiens	110-113